文献速递类风湿关节炎

真实世界评估JAK抑制剂在难治性类风湿关节炎中的疗效与耐受性

Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2024-10-30

研究纳入2018至2022年间启动JAK抑制剂的类风湿关节炎患者,将符合EULAR难治性RA(D2TRA)标准的45例与29例活动性非D2TRA患者比较。两组DAS28及DAS28-CRP从基线至首次随访(JAKi启动后6个月)的下降均显著且相似,末次随访时保持稳定;应答率、缓解率及低疾病活动度比例相似,停药率组间无显著差异(p=0.36)。JAKi在D2TRA中降低疾病活动的程度与非D2TRA活动性患者相同,耐受性相当,结局在很大程度上取决于年龄和/或心血管危险因素。

要点

  • D2TRA组45例与非D2TRA活动性组29例,DAS28及DAS28-CRP自基线至首次随访下降均显著且两组相似。
  • 首次随访至末次随访两组DAS28及DAS28-CRP保持稳定,应答率与缓解/低疾病活动度比例相似。
  • 35例(42%)停药,平均观察20±10个月,组间停药率无显著差异(p=0.36)。

核心结论

  • JAKi降低D2TRA患者疾病活动的程度与活动性非D2TRA患者相同。
  • 两组耐受性相当,结局在很大程度上取决于年龄和/或心血管危险因素的存在。

研究设计与样本

  • 纳入2018至2022年间启动JAKi的类风湿关节炎患者,符合EULAR D2TRA标准的患者与活动性非D2TRA患者进行比较。
  • 疗效在首次随访(JAKi启动后6个月)和截至2022年12月的末次可用随访时评估。

主要发现

  • 45例D2TRA患者(均呈现疾病活动征象:影像学、CRP水平)与29例活动性非D2TRA患者比较。
  • DAS28及DAS28-CRP从基线至首次随访的下降显著且两组相似,校正既往靶向治疗数量与暴露时长等因素前后均如此。
  • DAS28及DAS28-CRP在首次随访至末次随访期间两组均保持稳定。
  • 首次随访及末次随访时应答者比例及达到缓解或低疾病活动度的患者比例两组相似。
  • 平均观察20±10个月期间35例(42%)停用JAKi,组间停药率无显著差异(p=0.36),因无效和副作用停药分布均匀。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and tolerability of JAK inhibitors (JAKi) in patients with difficult-to-treat rheumatoid arthritis (D2TRA) in clinical practice. METHODS: We included RA patients initiating a JAKi between 2018 and 2022. Patients meeting EULAR criteria for D2TRA were compared to active non-D2TRA patients. Efficacy was evaluated at the first visit (FV) (6 months following JAKi initiation) and the last available visit (LV) up to December 2022. RESULTS: 45 patients with D2TRA, all presenting signs of disease activity (imaging, CRP levels), were compared to 29 active non-D2TRA. DAS28 and DAS28-CRP reduction from baseline to FV was significant and similar between both groups, before and after adjusting for several factors including the number and exposure duration to previous targeted therapies. DAS28 and DAS28-CRP remained stable in both groups between FV and LV. The proportion of responders and patients achieving remission or low disease activity at FV and LV was similar in both groups. Thirty-five patients (42 %) discontinued JAKi over a mean observation period of 20±10 months, with no significant difference in discontinuation rates between groups (p = 0.36). Discontinuations due to inefficacy and side effects were evenly distributed. Frequency of infections, herpes zoster, myocardial infarctions, and venous thromboembolism was similar between groups, with a higher likelihood in patients aged ≥65 years and/or with at least one cardiovascular risk factor (30/39, 77 %). CONCLUSION: JAKi effectively reduced disease activity in D2TRA patients with the same extent as active non-D2TRA patients. Tolerability profiles were comparable, with outcomes largely dependent on the presence of age and/or cardiovascular risk factors. Haut du formulaire.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Al Tabaa O, Hecquet S, Thomas M, et al. Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis. Semin Arthritis Rheum. 2024. PMID: 39509839. doi:10.1016/j.semarthrit.2024.152572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。